Kellerin alleviates cerebral ischemic injury by inhibiting ferroptosis via targeting Akt-mediated transcriptional activation of Nrf2. 2024

Yan Mi, and Yongping Wang, and Yeshu Liu, and Wen Dang, and Libin Xu, and Shaowen Tan, and Linge Liu, and Gang Chen, and Yueyang Liu, and Ning Li, and Yue Hou
Key Laboratory of Bioresource Research and Development of Liaoning Province, College of Life and Health Sciences, National Frontiers Science Center for Industrial Intelligence and Systems Optimization, Key Laboratory of Data Analytics and Optimization for Smart Industry, Ministry of Education, Northeastern University, Shenyang, PR China.

BACKGROUND Ischemic stroke (IS) is characterized as a detrimental cerebrovascular disease with high mortality and disability. Ferroptosis is a novel mechanism involved in neuronal death. There is a close connection between IS and ferroptosis, and inhibiting ferroptosis may provide an effective strategy for treating IS. Our previous investigations have discovered that kellerin, the active compound of Ferula sinkiangensis K. M. Shen, possesses the capability to shield against cerebral ischemia injury. OBJECTIVE Our objective is to clarify the relationship between the neuroprotective properties of kellerin against IS and its ability to modulate ferroptosis, and investigate the underlying regulatory pathway. METHODS We investigated the impact and mechanism of kellerin in C57BL/6 mice underwent middle cerebral artery occlusion/reperfusion (MCAO/R) as well as SH-SY5Y cells exposed to oxygen-glucose deprivation/ re-oxygenation (OGD/R). METHODS The roles of kellerin on neurological severity, cerebral infarction and edema were investigated in vivo. The regulatory impacts of kellerin on ferroptosis, mitochondrial damage and Akt/Nrf2 pathway were explored. Molecular docking combined with drug affinity responsive target stability assay (DARTS) and cellular thermal shift assay (CETSA) were performed to analyze the potential target proteins for kellerin. RESULTS Kellerin protected against IS and inhibited ferroptosis in vivo. Meanwhile, kellerin improved the neuronal damage caused by OGD/R and suppressed ferroptosis by inhibiting the production of mitochondrial ROS in vitro. Further we found that kellerin directly interacted with Akt and enhanced its phosphorylation, leading to the increase of Nrf2 nuclear translocation and its downstream antioxidant genes expression. Moreover, kellerin's inhibitory effect on ferroptosis and mitochondrial ROS release was eliminated by inhibiting Akt/Nrf2 pathway. CONCLUSIONS Our study firstly demonstrates that the neuroprotective properties of kellerin against IS are related to suppressing ferroptosis through inhibiting the production of mitochondrial ROS, in which its modulation on Akt-mediated transcriptional activation of Nrf2 plays an important role. This finding shed light on the potential mechanism that kellerin exerts therapeutic effects in IS.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D002545 Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. Cerebral Ischemia,Ischemic Encephalopathy,Encephalopathy, Ischemic,Ischemia, Cerebral,Brain Ischemias,Cerebral Ischemias,Ischemia, Brain,Ischemias, Cerebral,Ischemic Encephalopathies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000079403 Ferroptosis A form of REGULATED CELL DEATH initiated by oxidative perturbations of the intracellular microenvironment that is under constitutive control by glutathione peroxidase 4 and can be inhibited by iron chelators and lipophilic antioxidants. Oxytosis
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D015427 Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA. Ischemia-Reperfusion Injury,Injury, Ischemia-Reperfusion,Injury, Reperfusion,Reperfusion Damage,Damage, Reperfusion,Injury, Ischemia Reperfusion,Ischemia Reperfusion Injury,Ischemia-Reperfusion Injuries,Reperfusion Damages,Reperfusion Injuries
D015533 Transcriptional Activation Processes that stimulate the GENETIC TRANSCRIPTION of a gene or set of genes. Gene Activation,Genetic Induction,Transactivation,Induction, Genetic,Trans-Activation, Genetic,Transcription Activation,Activation, Gene,Activation, Transcription,Activation, Transcriptional,Genetic Trans-Activation,Trans Activation, Genetic
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Yan Mi, and Yongping Wang, and Yeshu Liu, and Wen Dang, and Libin Xu, and Shaowen Tan, and Linge Liu, and Gang Chen, and Yueyang Liu, and Ning Li, and Yue Hou
December 2023, European journal of pharmacology,
Yan Mi, and Yongping Wang, and Yeshu Liu, and Wen Dang, and Libin Xu, and Shaowen Tan, and Linge Liu, and Gang Chen, and Yueyang Liu, and Ning Li, and Yue Hou
February 2024, Acta pharmacologica Sinica,
Yan Mi, and Yongping Wang, and Yeshu Liu, and Wen Dang, and Libin Xu, and Shaowen Tan, and Linge Liu, and Gang Chen, and Yueyang Liu, and Ning Li, and Yue Hou
January 2022, Oxidative medicine and cellular longevity,
Yan Mi, and Yongping Wang, and Yeshu Liu, and Wen Dang, and Libin Xu, and Shaowen Tan, and Linge Liu, and Gang Chen, and Yueyang Liu, and Ning Li, and Yue Hou
April 2022, CNS neuroscience & therapeutics,
Yan Mi, and Yongping Wang, and Yeshu Liu, and Wen Dang, and Libin Xu, and Shaowen Tan, and Linge Liu, and Gang Chen, and Yueyang Liu, and Ning Li, and Yue Hou
January 2022, BioMed research international,
Yan Mi, and Yongping Wang, and Yeshu Liu, and Wen Dang, and Libin Xu, and Shaowen Tan, and Linge Liu, and Gang Chen, and Yueyang Liu, and Ning Li, and Yue Hou
August 2023, Physiological research,
Yan Mi, and Yongping Wang, and Yeshu Liu, and Wen Dang, and Libin Xu, and Shaowen Tan, and Linge Liu, and Gang Chen, and Yueyang Liu, and Ning Li, and Yue Hou
October 2023, Brain and behavior,
Yan Mi, and Yongping Wang, and Yeshu Liu, and Wen Dang, and Libin Xu, and Shaowen Tan, and Linge Liu, and Gang Chen, and Yueyang Liu, and Ning Li, and Yue Hou
March 2024, CNS neuroscience & therapeutics,
Yan Mi, and Yongping Wang, and Yeshu Liu, and Wen Dang, and Libin Xu, and Shaowen Tan, and Linge Liu, and Gang Chen, and Yueyang Liu, and Ning Li, and Yue Hou
September 2023, Amino acids,
Yan Mi, and Yongping Wang, and Yeshu Liu, and Wen Dang, and Libin Xu, and Shaowen Tan, and Linge Liu, and Gang Chen, and Yueyang Liu, and Ning Li, and Yue Hou
November 2023, Free radical biology & medicine,
Copied contents to your clipboard!